BOT 2.41% 40.5¢ botanix pharmaceuticals ltd

Where will we be in 12 months time?, page-195

  1. 4,192 Posts.
    lightbulb Created with Sketch. 5464
    I am encouraged that Botanix said that 50% of dermatologists they spoke with would try Sofdra as first line, and they plan on having a big sales force visiting those 4500 dermatologists.

    Their sales and market penetration plan, looks very aggressive, and I don't know if Kaken have taken steps anything like what BOT are proposing.

    Of interest, 85% of patients for the BOT trial said they felt an improvement, whereas only around 65% from qbrexa trial ( current best approved treatment ) said they felt improvement. The gravametric sweat reduction was similar at close to 70% for the two products. Price is 600 to 700 per month for qbrexa.

    So while not 100%, according to the patients, 85% vs 65%, its a better product than the only FDA approved treatment currently available , and will be at a similar price.
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
40.5¢
Change
-0.010(2.41%)
Mkt cap ! $734.6M
Open High Low Value Volume
42.0¢ 42.5¢ 39.5¢ $3.680M 8.989M

Buyers (Bids)

No. Vol. Price($)
18 297011 40.0¢
 

Sellers (Offers)

Price($) Vol. No.
40.5¢ 12027 3
View Market Depth
Last trade - 16.10pm 17/09/2024 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.